Sander van Deventer, MD, PhD

Sander is currently an Operating Partner after having served as (Managing) Partner at Forbion for three consecutive funds and continues to have a leading role in the scientific evaluation process of investment opportunities by the Investment Team.

Sander van Deventer is a renowned physician-scientist and entrepreneur with over 25 years of experience in drug development, particularly in mucosal inflammation, and antibody and gene therapy. He has played a pivotal role in the development and commercialization of groundbreaking therapies, including Remicade (the first commercial monoclonal antibody), Glybera (the first gene therapy approved in the Western world), and Hemgenix (a landmark gene therapy for hemophilia B). He is also a serial biotech founder (Amsterdam Molecular Therapeutics, which preceded uniQure, Dezima Pharma, VectorY Therapeutics) and a co-founder of Forbion. He has acted as CSO, CEO and CMO roles in private and Nasdaq -listed biotech companies and served on multiple boards of private and listed biotech companies.

He was board-certified as an internist and gastroenterologist and served as a professor of Medicine and Gastroenterology at the Universities of Amsterdam and Leiden. Sander van Deventer is a prolific scientist, authoring more than 600 scientific papers (with more than 70,000 citations), and supervising more than 40 PhD students.